InspireMD FCF/Debt

What does InspireMD do? InspireMD, Inc. generates revenue through the commercialization of its MicroNet stent platform technology, which includes the MicroNet micron mesh sleeve for embolic protection during stenting procedures. The company markets the CGuard carotid embolic prevention system (CGuard EPS), combining MicroNet with a self-expandable nitinol stent for carotid artery applications, and the MGuard Prime Embolic Protection System (MGuard Prime EPS) for acute coronary syndromes and saphenous vein graft interventions. In the European Union, InspireMD sells MGuard Prime EPS, a bare-metal cobalt-chromium stent, for coronary disease treatment. The company is also developing the neurovascular flow diverter NGuard for endovascular use. The primary buyers of InspireMD's products are healthcare providers, including hospitals and clinics specializing in vascular and coronary interventions. These institutions purchase the MicroNet, CGuard EPS, and MGuard Prime EPS to enhance procedural safety and outcomes during stent implantation. The European Union represents a key market for the MGuard Prime EPS, where it is marketed as a treatment option for coronary disease. The company's development of NGuard indicates a strategic focus on expanding its product portfolio into neurovascular applications. InspireMD's product segments are defined by clinical applications: carotid artery procedures (CGuard EPS), acute coronary syndromes (MGuard Prime EPS), and coronary disease treatment (MGuard Prime EPS in the EU). The MicroNet technology serves as a foundational component across multiple product lines, providing embolic protection. The company's revenue streams are driven by direct sales of these medical devices to healthcare institutions, with the EU market being a significant commercial focus for MGuard Prime EPS. InspireMD is one of the most popular companies on Eulerpool.